76 results about "Seizure Disorders" patented technology

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

The present invention relates to a novel class of bicyclic derivatives that function as small-molecule KCQN2 / 3 (Kv7.2 / 3) potassium channel activators, along with their pharmaceutical composition, method of preparation, and therapeutic applications. These compounds, represented by Formula (I), and defined by specific substituents and structural characteristics as described in the specification. By modulating or enhancing the activation of Kv7.2 / 3 potassium channels, these derivatives hold therapeutic potential for treating seizure disorders and other conditions influenced by potassium ion channel modulation.

In certain embodiments, the present disclosure is directed to methods for treating disorders, including depressive disorders, seizure disorders, and anhedonia, in a pediatric subject, wherein the methods comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, A-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6- dimethylphenyl]-3,3-dimethylbutanamide (azetukalner), or a pharmaceutically acceptable salt thereof, to the pediatric subject, for example, under fed conditions.

Described herein, in part, are methods useful for preventing and / or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as Parkinson's disease, psychiatric disorders (e.g., mood disorder (e.g., major depressive disorder)), pain, tremor (e.g., essential tremor), seizures (e.g., absence seizures), epilepsy, or an epilepsy syndrome (e.g., juvenile myoclonic epilepsy). The present invention further comprises methods for modulating the function of a T-type calcium channel and methods of administering a titrated dosage of a T-type calcium channel antagonist.

Compositions and methods for treating a seizure disorder with a compound according to Formula (I), or pharmaceutically acceptable salts thereof, are provided. The compositions and methods may be used to improve one or more symptoms of a seizure disorder. Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

The disclosure provides an injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and sulfobutyl ether-β-cyclodextrin may be in an inclusion complex. The disclosure also provides a lyophilized powder of the ganaxolone / sulfobutyl ether-β-cyclodextrin formulation that may be reconstituted in water for injection. The disclosure provides a method of treating a patient having a seizure disorder, stroke, or traumatic brain injury, comprising administering an effective amount of the injectable ganaxolone formulation comprising ganaxolone, sulfobutyl ether-β-cyclodextrin; and water. The disclosure also provides combination methods in which the injectable ganaxolone / sulfobutyl ether-β-cyclodextrin formulation is administered in combination with at least one additional active agent.

To provide compositions and methods for treating and preventing cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, and addiction.SOLUTION: Also provided are methods for the diagnosis and monitoring of cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, addiction, and other conditions such as convulsion or seizure. These compositions comprise fatty acid compounds and salts thereof which may be administered either alone, in combination with other medicaments, or as part of various treatment regimens. The provided compositions are effective for modulating markers, including, but not limited to, behavior associated with cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, opiate addiction, and other related conditions. Methods for administering the compositions are also provided.SELECTED DRAWING: Figure 1

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and / or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

The present disclosure encompasses novel benzamide enaminone compounds and pharmaceutically acceptable salts thereof and compositions including such compounds and pharmaceutically acceptable salts. The disclosure further encompasses methods of treating a subject at risk of having a seizure and / or methods of reducing or preventing the occurrence or severity of a seizure or seizure disorder associated therewith by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof or a composition thereof. In some embodiments, the disclosure encompasses compositions and combinations of agents that act synergistically to treat, prevent, or inhibit the occurrence of a seizure or a seizure disorder.

Provided are crystalline forms of 3-(7-chloro-1H-indazol-5-yl)-2,5-bis(trifluoromethyl)-3H-imidazo[4,5-b]pyridine, pharmaceutical compositions comprising the crystalline form, and their use in treating conditions associated with TARP γ8-dependent AMPA activity, such as epilepsy, epileptic disorders, seizures, seizure disorders, pain, psychiatric diseases, or neurodegenerative diseases.

Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1) mutations, and 4-phenylbutyrate, or the pharmaceutically acceptable salt thereof, is administered at a dose of 75 mg / kg / day to 125 mg / kg / day. In another embodiment, the method comprises combined GAT-1 gene therapy combined with administration of 4-phenylbutyrate.

Provided herein are methods of treating a seizure disorder in a subject in need thereof comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Also provided are methods of treating a pain, neurological, or psychiatric disorder, and methods of administering seletracetam to a subject comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Various pharmaceutical formulations comprising seletracetam, e.g., an orally disintegrating tablet and a mucoadhesive film, and a nasal spray device or oromucosal spray device comprising seletracetam are also provided.

Provided are methods of treating a subject with a SCN2A-related disorder, e.g., Developmental and Epileptic Encephalopathies (DEE), comprising administering to the subject an oligomeric compound. Also provided are methods of reducing frequency of seizures experienced by a subject with a SCN2A-related disorder, comprising administering to the subject an oligomeric compound.

Methods and compositions for treating a patient suffering from Huntington's disease or treating symptoms thereof are disclosed. The methods comprise administering to the patient an effective amount of a heteroaryl ketone fused aza-naphthane glucocorticoid receptor modulator (GRM) or an octahydro fused aza-naphthane GRM. In an embodiment, the GRM is Dargencolan. In some embodiments, the GRM is zaltile blue. In embodiments, the GRM is administered orally. In some embodiments, the GRM is administered daily; in other embodiments, the GRM is administered in a regimen, such as once every day, once every three days, once per week, or other administration regimen. The symptoms of Huntington's disease that can be treated by the methods described herein include, but are not limited to, motor symptoms (e.g., muscle weakness, posture abnormalities, walking difficulty, dysphagia) and neurological or psychological symptoms (e.g., seizure, amnesia, consciousness disorder, impaired verbal ability, delirium, depression, anxiety).

The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.

The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) with DEPDC5 gene mutation. In a further embodiment the types of seizures include tonic, tonic-clonic and focal seizures without impairment. Preferably the dose of CBD is between 5 mg / kg / day to 50 mg / kg / day.

Compositions and methods for treating a seizure disorder with a compound according to Formula (I), or pharmaceutically acceptable salts thereof, are provided. The compositions and methods may be used to improve one or more symptoms of a seizure disorder.Formula (I):or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.

The application provides a full hydrogel nerve electrode which is composed of four layers of hydrogel, namely a PSFD hydrogel layer, an LPPDMEA layer, a PSFD hydrogel layer and an MHD layer; the application also provides a preparation method and application of the full hydrogel nerve electrode. The application provides a PEDOT:PSS hydrogel conductive path with ultrahigh conductivity, which achieves a record capacity compared with a metal electrode; the introduction of dopamine in each layer of the full hydrogel nerve electrode ensures excellent interface compliance, so that the full hydrogel nerve electrode can be attached to the complex geometry of soft neural tissue and avoid interface mismatch between the conductive layer, the packaging layer, the shielding layer and the tissue-electrode interface; the natural polymer packaging layer improves compatibility, and the electromagnetic shielding layer is used to improve the signal-to-noise ratio. The full hydrogel nerve electrode can provide artificial electrical stimulation to the cerebral cortex of a rat during a seizure, and the prepared full hydrogel nerve electrode has the potential to become a valuable tool for better understanding the development, function and treatment of brain diseases and neurodegenerative diseases and neurodegenerative diseases.

The invention relates to a compound of formula (I), wherein, for example, - Z is representing a group (II), wherein R5 is representing NR6R7 group and wherein R6 and R7 represent independently a hydrogen - R4 is representing a O-aryl ring, - X is representing a NR2R3 group, wherein R2 and R3 are independently hydrogen and a (C1- C10)alkyl group, - R1 is representing a group (III), for its use in the prevention or the treatment of one of the following brain cancers chosen among: glioblastoma, astrocytoma, oligodendroglioma, medulloblastoma, ependymoma, meningioma, pineoblastoma, or in the prevention or the treatment of epilepsies or infantile epilepsies.

The present application discloses the use of alphaB-crystallin (CRYAB) as a marker for diagnosing or predicting a seizure disorder, particularly epilepsy. The present application also discloses the use of alphaB-crystallin in the preparation of a medicament or a kit for preventing or treating a seizure disorder, particularly epilepsy.

The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with Rett syndrome. In a further embodiment the types of seizures include tonic, tonic-clonic, absence seizures and focal seizures with impairment. Preferably the dose of CBD is between 5 mg / kg / day to 50 mg / kg / day.

Described herein are compositions that comprise Bumetanide Dibenzylamide for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, the present disclosure relates to methods and compositions for treating neurological disorders by administering agents that disrupt hypersynchronized neuronal activity without diminishing neuronal excitability. These compositions are useful for seizure disorders, epilepsy, and related indications.

The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.

Described herein are methods, compositions, products, and processes that utilize bioceramics in traditional agricultural and hydroponic systems. The bioceramics are utilized in powder form, as films, as aerosols, as water based treatment systems, or in solid forms. The methods and bioceramic compositions described here are also used for growing a Cannabis plant. One or more cannabinoids within the plant can be used in therapeutic compositions for the treatment of glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders.

The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and / or seizure disorders with the modified release compositions is also described.

This invention provides a treatment for patients with developmental and epileptic encephalopathy (DEE) that addresses behavioral problems in addition to seizures, without causing undesirable side effects such as somnolence, lethargy, withdrawal, and sedation. [Solution] A method is provided for treating behavioral problems and seizures in a subject having DEE, comprising administering an effective amount of cannabidiol (CBD) transdermally to the subject, wherein the behavioral problems are treated in the subject.